FIXKUPON EXPRESS ZERTIFIKAT - BIONTECH ADR Share Price

Certificat

DE000VX3LN26

Delayed Deutsche Boerse AG 15:44:01 10/05/2024 BST
465.6 EUR -0.08% Intraday chart for FIXKUPON EXPRESS ZERTIFIKAT - BIONTECH ADR
Current month+4.59%
1 month+1.63%
Date Price Change Volume
10/05/24 465.6 -0.08% 0
09/05/24 466 +3.66% 0
08/05/24 449.5 -1.60% 0
07/05/24 456.9 -1.52% 0
06/05/24 463.9 -0.93% 0

Delayed Quote Deutsche Boerse AG

Last update May 10, 2024 at 03:44 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
WKN VX3LN2
ISINDE000VX3LN26
Date issued 17/11/2021
Strike 262.2 $
Maturity 18/11/2024 (192 Days)
Parity 0.26 : 1
Emission price 1,000
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 1,019
Lowest since issue 427.6
Spread 3.71
Spread %0.80%

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
85.44 EUR
Average target price
106.8 EUR
Spread / Average Target
+25.02%
Consensus